JAMA Intern Med:药物QT延长与心律失常猝死风险

2020-03-03 MedSci MedSci原创

药物QT延长对突发性心律失常猝死影响可能被夸大

药物QT延长(QTPMs)是心源性猝死(SCD)的危险因素,近日研究人员考察了QTPM与尸检中突发性心律失常猝死(SAD)和非心律失常性猝死的相关性。

本次研究为POST SCD研究的一部分,根据处方单和死后毒理学发现确定的药物暴露量,用于计算总结性QTPM暴露量得分(范围0-20),采用QTPM评分评估QT延长药物暴露情况(1表示低;2-4表示中等;大于4表示高)。

研究分析了629名死者数据,死者平均年龄61.4岁,男性占69.8%,525名患者为疑似SCDs,104名创伤性死亡对照者。与创伤对照组相比,疑似SCDs的个体暴露程度更高,更可能服用QTPM(291例[55.4%] vs 28例[26.9%]; P<0.001)。低(比值比[OR]:2.25)和高(OR:6.70)暴露组相比, QTPMs使用均与SCD的风险增加相关。在验尸之后,在所有暴露组中,使用QTPM与非SAD(低危OR:2.88;中危OR:2.62;高危OR:14.22)的风险增加有关,但在所有暴露组中不与SAD相关。

研究认为,药物QT延长对突发性心律失常猝死影响可能被夸大。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=903960, encodeId=e32d903960a2, content=药物<a href='/topic/show?id=313515001e7' target=_blank style='color:#2F92EE;'>#QT延长#</a>与<a href='/topic/show?id=0d385098ecf' target=_blank style='color:#2F92EE;'>#心律失常#</a><a href='/topic/show?id=1b1a6816470' target=_blank style='color:#2F92EE;'>#猝死#</a>风险, beContent=null, objectType=article, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15001, encryptionId=313515001e7, topicName=QT延长), TopicDto(id=50987, encryptionId=0d385098ecf, topicName=心律失常), TopicDto(id=68164, encryptionId=1b1a6816470, topicName=猝死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Tue Dec 01 18:17:03 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901670, encodeId=20279016e07a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92a11943582, createdName=ALY, createdTime=Tue Nov 24 09:32:48 CST 2020, time=2020-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542929, encodeId=61691542929a0, content=<a href='/topic/show?id=a93d681e1ff' target=_blank style='color:#2F92EE;'>#猝死风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68171, encryptionId=a93d681e1ff, topicName=猝死风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=921913505832, createdName=ms3323097325231039, createdTime=Thu Mar 05 10:15:00 CST 2020, time=2020-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610312, encodeId=e17916103123e, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Mar 05 10:15:00 CST 2020, time=2020-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035945, encodeId=8c751035945d0, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Tue Mar 03 22:15:00 CST 2020, time=2020-03-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=903960, encodeId=e32d903960a2, content=药物<a href='/topic/show?id=313515001e7' target=_blank style='color:#2F92EE;'>#QT延长#</a>与<a href='/topic/show?id=0d385098ecf' target=_blank style='color:#2F92EE;'>#心律失常#</a><a href='/topic/show?id=1b1a6816470' target=_blank style='color:#2F92EE;'>#猝死#</a>风险, beContent=null, objectType=article, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15001, encryptionId=313515001e7, topicName=QT延长), TopicDto(id=50987, encryptionId=0d385098ecf, topicName=心律失常), TopicDto(id=68164, encryptionId=1b1a6816470, topicName=猝死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Tue Dec 01 18:17:03 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901670, encodeId=20279016e07a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92a11943582, createdName=ALY, createdTime=Tue Nov 24 09:32:48 CST 2020, time=2020-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542929, encodeId=61691542929a0, content=<a href='/topic/show?id=a93d681e1ff' target=_blank style='color:#2F92EE;'>#猝死风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68171, encryptionId=a93d681e1ff, topicName=猝死风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=921913505832, createdName=ms3323097325231039, createdTime=Thu Mar 05 10:15:00 CST 2020, time=2020-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610312, encodeId=e17916103123e, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Mar 05 10:15:00 CST 2020, time=2020-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035945, encodeId=8c751035945d0, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Tue Mar 03 22:15:00 CST 2020, time=2020-03-03, status=1, ipAttribution=)]
    2020-11-24 ALY

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=903960, encodeId=e32d903960a2, content=药物<a href='/topic/show?id=313515001e7' target=_blank style='color:#2F92EE;'>#QT延长#</a>与<a href='/topic/show?id=0d385098ecf' target=_blank style='color:#2F92EE;'>#心律失常#</a><a href='/topic/show?id=1b1a6816470' target=_blank style='color:#2F92EE;'>#猝死#</a>风险, beContent=null, objectType=article, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15001, encryptionId=313515001e7, topicName=QT延长), TopicDto(id=50987, encryptionId=0d385098ecf, topicName=心律失常), TopicDto(id=68164, encryptionId=1b1a6816470, topicName=猝死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Tue Dec 01 18:17:03 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901670, encodeId=20279016e07a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92a11943582, createdName=ALY, createdTime=Tue Nov 24 09:32:48 CST 2020, time=2020-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542929, encodeId=61691542929a0, content=<a href='/topic/show?id=a93d681e1ff' target=_blank style='color:#2F92EE;'>#猝死风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68171, encryptionId=a93d681e1ff, topicName=猝死风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=921913505832, createdName=ms3323097325231039, createdTime=Thu Mar 05 10:15:00 CST 2020, time=2020-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610312, encodeId=e17916103123e, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Mar 05 10:15:00 CST 2020, time=2020-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035945, encodeId=8c751035945d0, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Tue Mar 03 22:15:00 CST 2020, time=2020-03-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=903960, encodeId=e32d903960a2, content=药物<a href='/topic/show?id=313515001e7' target=_blank style='color:#2F92EE;'>#QT延长#</a>与<a href='/topic/show?id=0d385098ecf' target=_blank style='color:#2F92EE;'>#心律失常#</a><a href='/topic/show?id=1b1a6816470' target=_blank style='color:#2F92EE;'>#猝死#</a>风险, beContent=null, objectType=article, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15001, encryptionId=313515001e7, topicName=QT延长), TopicDto(id=50987, encryptionId=0d385098ecf, topicName=心律失常), TopicDto(id=68164, encryptionId=1b1a6816470, topicName=猝死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Tue Dec 01 18:17:03 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901670, encodeId=20279016e07a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92a11943582, createdName=ALY, createdTime=Tue Nov 24 09:32:48 CST 2020, time=2020-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542929, encodeId=61691542929a0, content=<a href='/topic/show?id=a93d681e1ff' target=_blank style='color:#2F92EE;'>#猝死风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68171, encryptionId=a93d681e1ff, topicName=猝死风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=921913505832, createdName=ms3323097325231039, createdTime=Thu Mar 05 10:15:00 CST 2020, time=2020-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610312, encodeId=e17916103123e, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Mar 05 10:15:00 CST 2020, time=2020-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035945, encodeId=8c751035945d0, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Tue Mar 03 22:15:00 CST 2020, time=2020-03-03, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=903960, encodeId=e32d903960a2, content=药物<a href='/topic/show?id=313515001e7' target=_blank style='color:#2F92EE;'>#QT延长#</a>与<a href='/topic/show?id=0d385098ecf' target=_blank style='color:#2F92EE;'>#心律失常#</a><a href='/topic/show?id=1b1a6816470' target=_blank style='color:#2F92EE;'>#猝死#</a>风险, beContent=null, objectType=article, channel=null, level=null, likeNumber=179, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15001, encryptionId=313515001e7, topicName=QT延长), TopicDto(id=50987, encryptionId=0d385098ecf, topicName=心律失常), TopicDto(id=68164, encryptionId=1b1a6816470, topicName=猝死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Tue Dec 01 18:17:03 CST 2020, time=2020-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901670, encodeId=20279016e07a, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=92a11943582, createdName=ALY, createdTime=Tue Nov 24 09:32:48 CST 2020, time=2020-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542929, encodeId=61691542929a0, content=<a href='/topic/show?id=a93d681e1ff' target=_blank style='color:#2F92EE;'>#猝死风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68171, encryptionId=a93d681e1ff, topicName=猝死风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=921913505832, createdName=ms3323097325231039, createdTime=Thu Mar 05 10:15:00 CST 2020, time=2020-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610312, encodeId=e17916103123e, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Mar 05 10:15:00 CST 2020, time=2020-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035945, encodeId=8c751035945d0, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Tue Mar 03 22:15:00 CST 2020, time=2020-03-03, status=1, ipAttribution=)]
    2020-03-03 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

相关资讯

Circulation:多种心律失常消融技术的优劣对比!

为了更有效的隔离肺静脉(PVI)和尽量降低房颤(AF)消融术后心律失常的复发率,现已开发出了新一代的消融技术。为对比各种消融技术的有效性和安全性,研究人员开展一多中心的随机化单盲试验,将346位药物难治性阵发性AF患者随机分至三组:接触力引导射频消融组(CF-RF,115人)、4分钟冷冻球囊消融组(Cryo-4,115人)和2分钟冷冻球囊消融组(Cryo-2,116人)。随访12个月。主要预后是在

《ACS和血运重建紧急情况下心律失常管理共识2019》解读

尽管心律失常的诊治在过去几十年已取得了重大进展,急性冠脉综合征(ACS)和血运重建紧急情况下发生的复杂性室上性和室性心律失常(VAs)的治疗仍是一个具有挑战性的临床问题。此前关于这类心律失常治疗的临床指南有限。2019年7月29日,欧洲心律学会(EHRA)与心力衰竭协会(HFA)、心律学会(HRS)、亚太心律学会(APHRS)、南非心律学会(CASSA)和拉丁美洲心律学会(LAHRS)合作,发布了

Circulation:MYL4突变相关房颤的亚稳定心房状态

心房颤动(房颤,AF)是临床上最常见的心律失常,与心力衰竭(心衰)、卒中和死亡率增加有关。由于人体原始组织的获取受限,加上现有体内外模型的机制问题,导致目前我们对AF的心肌基质仍了解甚少。利用MYH6:mCherry敲入报告基因细胞系,研究人员开发了一种可产生并高度提纯具有心房细胞生理和分子特征的多能干细胞来源的心肌细胞的实验方案,还模拟了一种人类MYL4突变,AF的一种少数明确的遗传因素之一。为

Hypertension:研究称干重体力活伤心!

运动是心血管疾病最重要的预防措施之一,国内外很多指南都强调加强体力活动可以减少心血管死亡。但是,体力活动(physical activity)是一个广泛的概念,体育运动、工作以及休闲时的体力活动对心血管的保护作用可能存在差异。

慢性肾功能衰竭继发甲状旁腺功能亢进患者无痛胃镜术中突发心律失常一例

患者,男,70岁,175 cm,71kg,一般状态可,ASAⅢ级,心功能Ⅲ级。因“泡沫尿17年余,规律透析3年余,右上腹胀痛10d余”入院。3年前诊断为:慢性肾脏病5期(尿毒症期);慢性肾小球肾炎;继发性甲状旁腺功能亢进。

PLos One:院外心脏骤停后低温治疗可以提高选定患者的1年生存率

低温治疗患者在神经系统预后改善方面未显示出明显的获益。室颤后接受TH治疗的患者1年生存率获益最大,而心脏停搏患者仅在年龄小于65岁时才有中等获益。